title: Long term treatment with oxaprotiline in patients with major depression.
abstract: 1) Four hundred thirty-seven patients with depressive illness were treated for up to 11 months with oxaprotiline (Ba-49802B) in a continuation study. 2) Results of this study suggest that oxaprotiline continued to be effective in alleviating depressive symptoms. 3) Additionally, evaluation of safety parameters failed to reveal any significant risk to patients who were treated with oxaprotiline over this extended period of time.
authors: CNS Division-Development Department, Pharmaceuticals Division, CIBA-GEIGY Corporation, Summit, NJ.
authors: R J
authors: RJ
authors: Katz
mesh_terms: D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
chemical_list: D000873:Anthracenes; D000928:Antidepressive Agents; D008376:Maprotiline; C027299:hydroxymaprotilin